BETA-JUDO

Beta-cell function in juvenile diabetes and obesity

 Coordinatore UPPSALA UNIVERSITET 

 Organization address address: SANKT OLOFSGATAN 10 B
city: UPPSALA
postcode: 751 05

contact info
Titolo: Dr.
Nome: Anders
Cognome: Alderborn
Email: send email
Telefono: +46 18 471 2577

 Nazionalità Coordinatore Sweden [SE]
 Sito del progetto http://betajudo.org/
 Totale costo 7˙899˙949 €
 EC contributo 5˙999˙779 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-02-01   -   2016-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UPPSALA UNIVERSITET

 Organization address address: SANKT OLOFSGATAN 10 B
city: UPPSALA
postcode: 751 05

contact info
Titolo: Dr.
Nome: Anders
Cognome: Alderborn
Email: send email
Telefono: +46 18 471 2577

SE (UPPSALA) coordinator 2˙442˙640.70
2    UNIVERSITAET LEIPZIG

 Organization address address: RITTERSTRASSE 26
city: LEIPZIG
postcode: 4109

contact info
Titolo: Mr.
Nome: Gerhard
Cognome: Fuchs
Email: send email
Telefono: +49 341 9735012
Fax: +49 341 9735009

DE (LEIPZIG) participant 740˙600.00
3    UNIVERSITE DE GENEVE

 Organization address address: Rue du General Dufour 24
city: GENEVE
postcode: 1211

contact info
Titolo: Dr.
Nome: Jean-Charles
Cognome: Sanchez
Email: send email
Telefono: 41223795486
Fax: 41223795502

CH (GENEVE) participant 546˙266.80
4    UNIVERSITE DU LUXEMBOURG

 Organization address address: AVENUE DE LA FAIENCERIE 162 A
city: LUXEMBOURG-VILLE
postcode: 1511

contact info
Titolo: Prof.
Nome: Eric
Cognome: Tschirhart
Email: send email
Telefono: +352 466644 6739

LU (LUXEMBOURG-VILLE) participant 380˙800.00
5    GEMEINNUTZIGE SALZBURGER LANDESKLINIKEN BETRIEBSGESELLSCHAFT

 Organization address city: Salzburg
postcode: 5020

contact info
Titolo: Mr.
Nome: Christoph
Cognome: Mandlier
Email: send email
Telefono: +43 662 4482 2080
Fax: +43 662 4482 2081

AT (Salzburg) participant 372˙600.00
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Renata
Cognome: Schaeffer
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 350˙400.00
7    UPPSALA LANS LANDSTING

 Organization address address: SLOTTSGRAND 2A
city: UPPSALA
postcode: 751 25

contact info
Titolo: Dr.
Nome: Sven-Arne
Cognome: åsman
Email: send email
Telefono: +46 18 6115783
Fax: +46 18 6116010

SE (UPPSALA) participant 311˙799.60
8    PIVOT BIOMEDICAL SCIENCE GMBH

 Organization address address: MAX-PLANCK-STRASSE 17
city: TRIER
postcode: 54296

contact info
Titolo: Dr.
Nome: Mike
Cognome: Otto
Email: send email
Telefono: +49 651 1461830
Fax: +49 651 992583921

DE (TRIER) participant 269˙690.40
9    SCANDINAVIAN CRO AB

 Organization address address: KUNGSGATAN 41
city: UPPSALA
postcode: 753 21

contact info
Titolo: Ms.
Nome: Ulrika
Cognome: Hammarström Lüllmaa
Email: send email
Telefono: +46 18 100 551

SE (UPPSALA) participant 244˙800.00
10    PROTEOSYS AG

 Organization address address: CARL ZEISSSTRASSE 51
city: MAINZ
postcode: 55129

contact info
Titolo: Mr.
Nome: Bernd
Cognome: Matuschek
Email: send email
Telefono: +49 6131 5019223
Fax: +49 6131 5019211

DE (MAINZ) participant 160˙981.50
11    PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG

 Organization address address: STRUBERGASSE 21
city: SALZBURG
postcode: 5020

contact info
Titolo: Dr.
Nome: Vera
Cognome: Coreth
Email: send email
Telefono: 436624000000000
Fax: 436624000000000

AT (SALZBURG) participant 110˙400.00
12    ASTRAZENECA UK LIMITED

 Organization address address: STANHOPE GATE 15
city: LONDON
postcode: W1K 1LN

contact info
Titolo: Dr.
Nome: Li
Cognome: Wang
Email: send email
Telefono: +46 31 7065954

UK (LONDON) participant 68˙800.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

childhood    secretion    normal    hypersecretion    children    drugs    young    individuals    intervention    accentuated    strategies    beta    principles    subjects    therapeutic    judo    insulin    interventions    adipocyte    additional    cell    obese    dm    cells    levels    islets    genes    obesity    human    translational    patient    genetic    brown    mellitus    diabetes      

 Obiettivo del progetto (Objective)

'The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T2DM, which is coupled to rise in childhood obesity. Accentuated insulin secretion is observed early in young obese individuals. In many subjects insulin hypersecretion is evident when insulin sensitivity is essentially normal. Based on these observations we propose insulin hypersecretion as an etiological factor promoting lipid deposition, insulin resistance, cellular dysfunction and death in insulin-producing beta-cells and insulin-target brown adipocytes. Pharmacology-based treatment strategies are limited for this growing patient group and the aim of the proposal is to identify novel strategies reducing insulin hypersecretion, which has not been considered a target for intervention in young obese individuals. To address the issue, pediatric obesity clinics and academic centres with focus on beta-cell biology, brown adipocyte imaging, transcript and protein profiling, genetics, epidemiology and bioinfomatics have formed a consortium with two SMEs specialized on biomarker discovery and clinical trials and one large drug company. In the project well-characterized European patient cohorts of more than 3000 obese children will be further characterized with regard to insulin secretion and brown adipocyte mass. Currently used drugs and new principles of intervention based on novel genes, idenitifed in the project and linked with insulin hypersecretion, will be examined for effects on insulin hypersecretion in translational work including the young obese subjects and isolated human islets. Following comprehensive analysis candidate compounds/principles attenuating insulin hypersecretion will be selected, from which novel therapeutic strategies are expected to emerge. Such therapeutic strategies will be of importance for afflicted individuals and European health economy and lead to new opportunities for European industry.'

Introduzione (Teaser)

Type 2 diabetes mellitus (T2DM) is increasingly prevalent among children due to a concomitant rise in obesity. Obtaining insight into the interplay between the two conditions could lead to the development of much-needed therapeutic interventions.

Descrizione progetto (Article)

T2DM is a metabolic disorder where the body is unable to produce or utilise insulin effectively. Since high insulin levels favour storage rather than combustion of energy, individuals with accentuated insulin responses could be at risk of developing obesity and T2DM.

To delineate if high insulin levels is an early phenomenon that dictates obesity development, the EU-funded 'Beta-cell function in juvenile diabetes and obesity' (http://www.betajudo.org (BETA-JUDO)) project is pursuing a translational approach. By bringing together researchers and clinicians across Europe, the project hopes to answer key questions regarding elevated insulin levels in young obese individuals. Additional objectives of the study include the elucidation of genetic predisposition factors alongside the development of pharmacological interventions.

Scientists are performing oral glucose tolerance tests in obese and normal weight children to characterise insulin secretion. Genetic analysis aims at identifying genes potentially associated with insulin traits in obese children. When obese children with high insulin levels were followed up, a drop in insulin levels could be observed. Some of these individuals developed T2DM.

A considerable part of the BETA-JUDO work is focused on the molecular mechanisms responsible for insulin hypersecretion from human pancreatic islets. An in vitro model for insulin hypersecretion, where islet cells are cultured, has been established and partners are in the process of evaluating various drugs that could normalise the aberrant phenotype. Additional characteristics associated with insulin hypersecretion are also being evaluated such as circulating levels of free fatty acids, as well as white and brown fat cells.

Taken together, the BETA-JUDO study will generate important knowledge on the association between insulin hypersecretion and childhood obesity. Project activities should help reduce obesity rates in Europe through increased awareness about the dismal outcome of childhood obesity and the importance of intervention strategies.

Altri progetti dello stesso programma (FP7-HEALTH)

BIOMAGSCAR (2012)

Biodegradable Magnetic Stent for Coronary Artery Luminal Regeneration

Read More  

COURAGE IN EUROPE (2009)

COURAGE in Europe - COllaborative Research on AGEing in Europe

Read More  

DIABAT (2011)

Recruitment and activation of brown adipocytes as preventive and curative therapy for type 2 diabetes

Read More